Highlights OncoCyte Corporation

Equities

OCX

US68235C2061

Market Closed - Nasdaq Other stock markets 21:00:00 24/06/2024 BST			5-day change	1st Jan Change
2.65 ^USD	-6.36%		-3.99%	+6.00%

06-18	OncoCyte Names Andrea James Chief Financial Officer	MT
06-17	OncoCyte Corporation Appoints Andrea James as Chief Financial Officer	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

OncoCyte Corporation Appoints Andrea James as Chief Financial Officer	06-17	CI
Oncocyte Corporation Announces Promising Results in A Phase 2 Clinical Trial	06-03	CI
Oncocyte Corporation Announces Favorable Oncocyte Vitgraft Kidney Study Results	05-30	CI
Earnings Flash (OCX) ONCOCYTE CORPORATION Reports Q1 Revenue $176,000, vs. Street Est of $0.4M	05-15	MT
OncoCyte Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Sector Update: Health Care Stocks Steady Pre-Bell Friday	04-12	MT
OncoCyte Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	04-12	CI
Oncocyte Corporation and Bio-Rad Laboratories, Inc. Partner on Global Launch of Transplant Assay	04-11	CI
Oncocyte Corporation Begins FDA Submissions Process for VitaGraft Transplant Assays	12-06	CI
OncoCyte Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
OncoCyte Says VitaGraft Kidney Diagnostic Test to Receive Medicare, Medicaid Coverage	28/08/23	MT
Oncocyte Corporation Announces Vitagraft Kidney Transplant Diagnostic Test Receives Cms Coverage	28/08/23	CI
Earnings Flash (OCX) ONCOCYTE CORPORATION Reports Q2 Revenue $463,000, vs. Street Est of $0.35M	10/08/23	MT
OncoCyte Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Oncocyte Corporation Announces the Publication of New Data Demonstrating Vitagraft Kidney's Novel Ability to Help Physicians Treat Kidney Transplant Patients	25/07/23	CI
Earnings Flash (OCX) ONCOCYTE CORPORATION Posts Q1 Revenue $297,000, vs. Street Est of $340,000	11/05/23	MT
OncoCyte Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
Oncocyte Corporation Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer	07/04/23	CI
Earnings Flash (OCX) ONCOCYTE CORPORATION Posts Q4 Revenue $958,000, vs. Street Est of $1.42M	31/03/23	MT
OncoCyte Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights OncoCyte Corporation

Equities

OCX

US68235C2061

Highlights

Filters